Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing risk factors: prevention of inhibitors in haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Mar 2010

Chambost H

Abstract excerpt

The formation of antibodies against factor VIII or factor IX that inhibit replacement therapy is currently the most serious treatment-related complication faced by patients with haemophilia. This review highlights non-modifiable and modifiable risk factors that determine the development of these antibodies. The non-modifiable risk factors include patient genotype for haemophilia, immunogenotype, ethnicity and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Blood Coagulation Factor Inhibitors
Share to Cytokines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor IX

Share to Factor VIII

Share to Hemophilia A

Share to Infant

Share to Infant, Newborn

Source

Identifiers

PMID: 20132333
DOI: 10.1111/j.1365-2516.2009.02197.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing risk factors: prevention of inhibitors in haemophilia.PMID 20132333Read ↗

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?Semantic proximity Read ↗

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.Semantic proximity Read ↗

Inhibitors in haemophilia: pathophysiology.Semantic proximity Read ↗

Prevention and prediction of inhibitor risk.Semantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

Key issues in inhibitor management in patients with haemophilia.Semantic proximity Read ↗

Inhibitor development: patient-determined risk factors.Semantic proximity Read ↗

Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.Semantic proximity Read ↗

Factor VIII inhibitors.Semantic proximity Read ↗

Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit.Semantic proximity Read ↗

Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factorsSemantic proximity Read ↗

Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.